Course Preview

Disciplines: Pharmacists
Hours: 3 Contact Hours
Author(s): Corey E. Scheer, RPh, BS Pharm, PharmD, BCPP
Peer Reviewer(s):
  • Charles F. Caley, BS Pharm, PharmD, BCPP
  • Kirstyn M. Kameg, DNP, PMHNP-BC
Item#: Y8000
Contents: 1 Course Book (44 pages)
Western Schools is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education
Sign up for the Western Schools 365 Online Membership

Antidepressants, 2nd Edition

Price $12.95
Item # Y8000
When available, the Online Course format is included with the hard copy, eBook, or audio book formats!

Start Date: September 16, 2016

Expiration Date: September 15, 2019


The purpose of this course is to provide current, evidence-based information for pharmacists (RPhs) on the mechanisms of action, pharmacokinetic and pharmacodynamics parameters, potential adverse events, adverse event management strategies, and special considerations affecting medication use and selection for medications used to treat depressive disorders. Although many medications used to treat depression have been around for several decades, new medications are constantly under development and it is important that healthcare professionals stay abreast of these new developments. In addition, the way that many of these medications with antidepressant properties are used in clinical practice continues to change. Although only some RPhs may specialize in mental health, all will encounter patients with mental health conditions such as major depressive disorder. This course is designed for RPhs practicing in all settings who may encounter patients taking antidepressants or be involved in initiating treatment with antidepressants.


Universal Activity Number (UAN) - 0607-0000-16-001-H01-P

Type of Activity - Knowledge

Topic Designator - 01– Disease State Management/Drug Therapy

Course Objectives

  • Define major theories of the pathophysiology of depression.
  • Describe the mechanisms of action of medications used to treat depressive disorders.
  • Identify potential adverse events and implement monitoring parameters for antidepressant medications.
  • Describe pharmacokinetic and pharmacodynamic parameters of antidepressant medications that may affect medication selection.
  • Describe upcoming and novel treatment options for depressive disorders.
  • Apply knowledge to the pharmacologic management of a patient case.


Corey E. Scheer, RPh, BS Pharm, PharmD, BCPP, completed her BS Pharm and Doctor of Pharmacy degree at the University of Connecticut and then went on to complete a postgraduate year 1 residency at the University of Rochester Medical Center in Rochester, New York. From there, she completed a postgraduate year 2 residency specializing in psychiatric pharmacy at the Tuscaloosa VA Medical Center in Tuscaloosa, Alabama. After completing 2 years of residency, Dr. Scheer accepted a position as Clinical Assistant Professor of Pharmacy Practice at Western New England University College of Pharmacy, where she teaches psychiatry therapeutics and a case-based laboratory course, in addition to acting as a preceptor for final-year Doctor of Pharmacy students on clinical rotations at her practice site, Providence Behavioral Health Hospital. She is a board-certified psychiatric pharmacist. She has been teaching in the Doctor of Pharmacy program for 3 years. 


Charles F. Caley, BS Pharm, PharmD, BCPP, is Clinical Professor of Pharmacy Practice at the University of Connecticut School of Pharmacy and is a board-certified psychiatric pharmacist providing clinical and education services at the Institute of Living in Hartford, Connecticut. He received his BS in Pharmacy and PharmD degrees from the University of Rhode Island College of Pharmacy, and then completed a 2-year specialty residency in psychiatric pharmacy at the Institute of Mental Health in Cranston, Rhode Island, and at Eastern State Hospital in Medical Lake, Washington. Dr. Caley is also an active provider of professional service to the psychiatric pharmacy profession. He is a founding member of the College of Psychiatric and Neurologic Pharmacists (CPNP) and served as the organization’s president in 2005-2006. Currently he is the Past President of the Board of Directors for the CPNP Foundation. Dr. Caley actively generates scholarship centered on psychotropic medications, and he has published in journals of pharmacy, psychiatry, and college health. In addition, he provides professional education presentations to audiences at the local, regional, and national level. Currently, Dr. Caley is working with others to transform the practice of pharmacy in Connecticut by being an active provider of comprehensive medication management services and also by leading a national effort to formally organize and recognize the practice efforts of those pharmacists in community mental health pharmacy settings.

Kirstyn M. Kameg, DNP, PMHNP-BC, is a Professor of Nursing and is currently the coordinator of the Psychiatric Mental Health Nurse Practitioner program at Robert Morris University. She teaches doctoral level courses in psychopharmacology, neuroanatomy, and neurophysiology. She also maintains a private practice as a nurse practitioner treating adolescent and adult patients diagnosed with a variety of psychiatric diagnoses.

  • Courses must be completed on or before the expiration date noted in the course description above.
  • You must score 75% or higher on the final exam and complete the course evaluation to pass this course and have your record transmitted to your NABP e-Profile account.
  • Through our review processes, Western Schools ensures that this course content is presented in a balanced, unbiased manner and is free from commercial influence. It is Western Schools’ policy not to accept commercial support.
  • All persons involved in the planning and development of this course have disclosed no relevant financial relationships or other conflicts of interest related to the course content.